Redeye comments on Scandion publishing positive CORIST phase II part 1 results. As expected, part 1 determined a well-tolerated recommended dose for part 2. Further, preliminary efficacy measures provided encouraging hints about SCO-101’s effectiveness. Overall, we believe these results highlight SCO-101’s potential to resensitize patients to chemotherapy, and we reiterate our base case valuation.